GCOR Genencor International, (MM)

Protein Polymer Technologies and Genencor International Expand Exclusive License Agreement SAN DIEGO, March 30 /PRNewswire-FirstCall/ -- Protein Polymer Technologies, Inc. (OTC:PPTI) (BULLETIN BOARD: PPTI) , today announced the expansion of its license agreement with Genencor International, Inc. (NASDAQ:GCOR), and receipt of an associated payment. The license agreement was initially established in December 2000, granting Genencor worldwide exclusive rights to industrial applications of PPTI's proprietary protein polymer design and production technology. Under the amended agreement, the licensed rights have been expanded to include personal care product applications. PPTI continues to retain all rights to its technology for use in the development and commercialization of medical products. The payment received, and additional annual payments through 2010, are in consideration for the amended license rights. Royalties will also be payable on sales of products. Genencor International is a world leader in the development and manufacture of industrial enzymes and other biotechnology products. Protein Polymer Technologies, whose internal product focus is primarily medical, holds the fundamental patents on the design and development of de novo proteins that in form are highly repetitive polymers with unique physical and biological properties. "Our expanded agreement with the additional payments reflects not only Genencor's progress towards commercial products based on our technology, but also our progress in realizing returns on the full breadth of our technology," said PPTI's Chief Executive Officer, J. Thomas Parmeter. Protein Polymer Technologies, Inc., is a San Diego-based company focused on developing products to improve medical and surgical outcomes. From its inception in 1988, PPTI has been a pioneer in protein design and synthesis, developing an extensive portfolio of proprietary biomaterials. These genetically engineered biomaterials are high molecular weight proteins, processed into products with physical and biological characteristics tailored to specific clinical performance requirements. Targeted products include urethral bulking agents for the treatment of stress urinary incontinence, dermal augmentation products for cosmetic and reconstructive surgery, surgical adhesives and sealants, scaffolds for wound healing and tissue engineering, and depots for local drug delivery. To date, PPTI has been issued twenty-five U.S. patents on its core technology with corresponding issued and pending patents in key international markets. This press release contains forward-looking statements that are based on management's views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company's activities include raising adequate capital to continue operations scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company's 2003 Annual Report Form 10-KSB and subsequent three 2004 Quarterly Reports Form 10QSB, and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements. DATASOURCE: Protein Polymer Technologies, Inc. CONTACT: J. Thomas Parmeter, President, or John Flowers, Vice President, Planning and Operations, both of Protein Polymer Technologies, Inc., +1-858-558-6064,

Copyright